PATIENT RELATED PROGNOSTIC FACTORS IN HEAD NECK CANCERS: COMORBIDITIES AND AGE - FOCUS ON TUBERCULOSIS AND ON GERIATRIC ONCOLOGY
DOI:
https://doi.org/10.22551/q3bew573Abstract
Head and neck cancers are often diagnosed in the late stages, the evolution being often unfavorable even if the multimodal treatment is administered correctly. In principle, it can be considered that there are three categories of factors involved in prognosis: patient, tumor and treatment related-factors. The aim of the study was to highlight the involvement of patient-related factors in the prognosis of locally advanced, recurrent and metastatic head and neck cancers. Materials and methods: After the initial selection, including the identification of cases treated in the Oncology Clinic and the Oncology outpatient clinic, the study group included 190 patients. Among them, after applying the general inclusion and exclusion criteria, 149 cases of head and neck cancers were selected. Patients admitted to the oncological record in the period 2002-2021 with all anatomical locations of head and neck cancers, stage III and IV: nasopharynx, oropharynx, larynx, hypopharynx, oral cavity, glands salivation, nasal cavity and paranasal sinuses, cervical lymph node metastases of unspecified starting point - Cancers with Unknown Primary (CUP). Results: The presence of comorbidities in the case of patients with head and neck cancer, but especially pulmonary tuberculosis, active, reactivated or sequelae, is associated with an unfavorable prognosis. Studies are needed to analyze in more detail the implication of the association between pulmonary tuberculosis and each subtype of head and neck cancer. Conclusions: There is an increased incidence of neurological pathologies, especially stroke compared to the results published in the literature. In our study, age >65 years was not identified as a significant prognostic factor, but a tendency to reduce survival to more than 2 years in the case of geriatric patients should be mentioned.
References
1. Gospodarowicz M, O'Sullivan B. Prognostic factors in cancer. Semin Surg Oncol 2003; 21(1): 13-18 / doi: 10.1002/ssu.10016.
2. Gorbunov EA, Wechsler J. Prognóza a prognostické faktory v onkologii a onkochirurgii (Prognosis and prognostic factors in oncology and oncologic surgery). Vnitr Lek 2004; 50(1): 61-65.
3. Hoesseini A, Sewnaik A, van den Besselaar BN, et al. Prognostic model for overall survival of head and neck cancer patients in the palliative phase. BMC Palliat Care 2024; 23(1): 54 / doi: 10.1186/ s12904-023-01325-y.
4. Kunkler IH, Audisio R, Belkacemi Y, et al SIOG Radiotherapy Task Force. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: The Interna-tional Society of Geriatric Oncology (SIOG) task force. Ann Oncol 2014; 25(11): 2134-2146 / doi: 10.1093/annonc/mdu104.
5. Stan MC, Georgescu D, Mireștean CC, Bădulescu F. Cancer and Diabetes: Predictive Factors in Patients with Metabolic Syndrome. Diagnostics (Basel) 2023; 13(16): 2647 / doi: 10.3390/diagnostics 13162647.
6. Mirestean CC, Iancu RI, Iancu DPT, Stan MC Badulescu F. Is the substitution of Cisplatin and 5-Flurouracil with Carboplatin and Capecitabine in the treatment of locally advanced head neck cancers (HNC) an option? A retrospective single center analysis. Bratisl Med J 2025 / doi: 10.1007/s44411-025 00050-7.
7. Mirestean CC, Stan MC, Badulescu F. Implications of diabetes in head and neck cancer - A single center real-world data. Bratisl Lek Listy 2023; 124(7): 549-552 / doi: 10.4149/ BLL_2023_085.
8. Pang P, Duan W, Liu S, Bai S, Ma Y, Li R, Liu F, Sun C. Clinical study of tuberculosis in the head and neck region-11 years' experience and a review of the literature. Emerg Microbes Infect 2018; 7(1):4 / doi: 10.1038/s41426-017-0008-7.
9. Vaid S, Lee YY, Rawat S, Luthra A, Shah D, Ahuja AT. Tuberculosis in the head and neck--a forgot-ten differential diagnosis. Clin Radiol 2010; 65(1): 73-81 / doi: 10.1016/j.crad.2009.09.004.
10. Lai SW, Lin CL, Liao KF. Head and neck cancer associated with increased rate of pulmonary tuber-culosis in a population-based cohort study. Medicine (Baltimore) 2017; 96(43): e8366 / doi: 10.1097/ MD.0000000000008366.
11. Qian X, Albers AE, Nguyen DTM, et al. Head and neck tuberculosis: Literature review and meta-analysis. Tuberculosis (Edinb) 2019; 116S: S78-S88 / doi: 10.1016/j.tube.2019.04.014.
12. Chan ED. Are there common threads in the susceptibility to cancer and tuberculosis? J Thorac Dis 2020; 12(5): 1776-1780 / doi: 10.21037/jtd.2020.03.114.
13. Preda M, Tănase BC, Zob DL, et al. The Bidirectional Relationship between Pulmonary Tuberculosis and Lung Cancer. Int J Environ Res Public Health 2023; 20(2): 1282 / doi: 10.3390/ijerph20021282.
14. Matsuo M. Development of active tuberculosis during treatment of head and neck carcinoma: a case series. J Med Case Rep 2019; 13(1):162 / doi: 10.1186/s13256-019-2055-2.
15. Piccirillo JF, Lacy PD, Basu A, Spitznagel EL. Development of a New Head and Neck Cancer–Specific Comorbidity Index. Arch Otolaryngol Head Neck Surg 2002; 128(10): 1172-1179 / doi:10.1001/archotol.128.10.117
16. Ruud Kjær EK, Jensen JS, Jakobsen KK, et al. The Impact of Comorbidity on Survival in Patients with Head and Neck Squamous Cell Carcinoma: A Nationwide Case-Control Study Spanning 35 Years. Front Oncol 2021; 10: 617184 / doi: 10.3389/fonc.2020.617184.
17. Takenaka Y, Takemoto N, Oya R, et al. Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan. Sci Rep 2017; 7(1): 7297 / doi: 10.1038/ s41598-017-07752-1.
18. Kallogjeri D, Piccirillo JF, Spitznagel EL Jr, Steyerberg EW. Comparison of Scoring Methods for ACE-27: Simpler Is Better. J Geriatr Oncol 2012; 3(3): 238-245 / doi: 10.1016/j.jgo.2012.01.006.
19. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118(13): 3377-3386 / doi: 10.1002/cncr.26646.
20. Mireștean CC, Iancu RI, Iancu DT. Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon-A Partnership with Unsolved Challenges: Dose, Fractionation, Volumes, Therapeutic Se-quence. Curr Oncol 2022; 29(10): 7388-7395 / doi: 10.3390/curroncol 29100580.
21. Chen H, Cantor A, Meyer J, et al. Can older cancer patients tolerate chemotherapy? A prospective pilot study Cancer 2003; 97(4): 1107-1114 / doi: 10.1002/cncr.11110.
22. Mireștean CC, Stan MC, Schenker M, et al. Immunotherapy with PD-1 Inhibitor Nivolumab in Re-current/Metastatic Platinum Refractory Head and Neck Cancers-Early Experiences from Romania and Literature Review. Diagnostics (Basel) 2023; 13(16): 2620 / doi: 10.3390/diagnostics13162620.
23. Mountzios G. Optimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapy. World J Clin Oncol 2015; 6(1): 7-15 / doi: 10.5306/ wjco.v 6. i1.7.
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 The Medical-Surgical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
